New seizure drug shows promise in large trial
NCT ID NCT04557085
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called cenobamate in 519 adults with partial onset seizures (focal seizures). Participants took cenobamate or a placebo alongside their usual seizure medications. The goal was to see if cenobamate could safely reduce seizure frequency. Results showed a significant decrease in seizures for those on cenobamate, supporting its use as an add-on therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL SEIZURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Site 1
Seoul, South Korea
-
Site 2
Tokyo, Japan
-
Site 3
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new daily pill tame focal seizures?
- Real-world safety of fycompa injection under the microscope for epilepsy patients
- New pill aims to curb focal seizures in adults
- New epilepsy drug RAP-219 enters final testing phase
- Could a zapping headband tame tough seizures?
- New epilepsy drug vormatrigine tested for Long-Term safety in 700 adults